CN107102142A - 检测腺癌的蛋白标志/标记 - Google Patents
检测腺癌的蛋白标志/标记 Download PDFInfo
- Publication number
- CN107102142A CN107102142A CN201710115906.1A CN201710115906A CN107102142A CN 107102142 A CN107102142 A CN 107102142A CN 201710115906 A CN201710115906 A CN 201710115906A CN 107102142 A CN107102142 A CN 107102142A
- Authority
- CN
- China
- Prior art keywords
- cancer
- antibody
- individual
- array
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 58
- 201000011510 cancer Diseases 0.000 title claims abstract description 54
- 210000004907 gland Anatomy 0.000 title claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 title abstract description 35
- 102000004169 proteins and genes Human genes 0.000 title abstract description 33
- 230000027455 binding Effects 0.000 claims abstract description 42
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims abstract description 37
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 25
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract description 10
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 6
- 238000002493 microarray Methods 0.000 claims description 31
- 108090000978 Interleukin-4 Proteins 0.000 claims description 9
- 210000000496 pancreas Anatomy 0.000 claims description 6
- 238000000034 method Methods 0.000 abstract description 57
- 238000012360 testing method Methods 0.000 abstract description 46
- 210000002966 serum Anatomy 0.000 abstract description 37
- 239000000523 sample Substances 0.000 description 56
- 235000018102 proteins Nutrition 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 25
- 239000000090 biomarker Substances 0.000 description 18
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 17
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 16
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 239000013068 control sample Substances 0.000 description 12
- 239000012491 analyte Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 238000011160 research Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 102000004506 Blood Proteins Human genes 0.000 description 8
- 108010017384 Blood Proteins Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 102100023688 Eotaxin Human genes 0.000 description 5
- 101710139422 Eotaxin Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012706 support-vector machine Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000010208 microarray analysis Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 3
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000012775 microarray technology Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 239000011049 pearl Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 206010073364 Ductal adenocarcinoma of pancreas Diseases 0.000 description 2
- 101001104083 Homo sapiens Rabphilin-3A Proteins 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102100040040 Rabphilin-3A Human genes 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920009405 Polyvinylidenefluoride (PVDF) Film Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102100032889 Sortilin Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002508 contact lithography Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000012336 endoscopic ultrasonography Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000007616 round robin method Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 108010014657 sortilin Proteins 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0705876.1 | 2007-03-27 | ||
| GB0705876A GB0705876D0 (en) | 2007-03-27 | 2007-03-27 | Method, array and use thereof |
| GB0712181A GB0712181D0 (en) | 2007-06-25 | 2007-06-25 | Method, array and use thereof |
| GB0712181.7 | 2007-06-25 | ||
| CN200880013776A CN101680896A (zh) | 2007-03-27 | 2008-03-25 | 检测腺癌的蛋白标志/标记 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880013776A Division CN101680896A (zh) | 2007-03-27 | 2008-03-25 | 检测腺癌的蛋白标志/标记 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107102142A true CN107102142A (zh) | 2017-08-29 |
Family
ID=39493874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710115906.1A Pending CN107102142A (zh) | 2007-03-27 | 2008-03-25 | 检测腺癌的蛋白标志/标记 |
| CN200880013776A Pending CN101680896A (zh) | 2007-03-27 | 2008-03-25 | 检测腺癌的蛋白标志/标记 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880013776A Pending CN101680896A (zh) | 2007-03-27 | 2008-03-25 | 检测腺癌的蛋白标志/标记 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20100105571A1 (enExample) |
| EP (3) | EP2140269B1 (enExample) |
| JP (3) | JP6115801B2 (enExample) |
| CN (2) | CN107102142A (enExample) |
| AU (3) | AU2008231575A1 (enExample) |
| CA (1) | CA2681899C (enExample) |
| DK (1) | DK2140269T3 (enExample) |
| ES (1) | ES2442919T3 (enExample) |
| PL (1) | PL2140269T3 (enExample) |
| WO (1) | WO2008117067A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| GB0723179D0 (en) * | 2007-11-27 | 2008-01-02 | Immunovia Ab | Diagnostic methods and arrays for use in the same |
| US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| EP2415877A3 (en) * | 2010-02-17 | 2012-02-15 | Deutsches Krebsforschungszentrum | Means and methods for diagnosing pancreatic cancer |
| GB201009798D0 (en) | 2010-06-11 | 2010-07-21 | Immunovia Ab | Method,array and use thereof |
| MX355020B (es) | 2010-07-09 | 2018-04-02 | Somalogic Inc | Biomarcadores de cancer de pulmon y usos de los mismos. |
| JP5931874B2 (ja) * | 2010-08-13 | 2016-06-08 | ソマロジック・インコーポレーテッド | 膵癌バイオマーカーおよびその使用 |
| GB201103726D0 (en) * | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| KR20150129932A (ko) | 2014-05-12 | 2015-11-23 | 연세대학교 산학협력단 | 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 |
| GB201516801D0 (en) * | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
| RU2627448C1 (ru) * | 2016-04-05 | 2017-08-08 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" | Способ иммуногистохимического выявления антигенов в препаратах органов продуктивных и непродуктивных животных длительного хранения в фиксаторах |
| GB201608192D0 (en) * | 2016-05-10 | 2016-06-22 | Immunovia Ab | Method, array and use thereof |
| GB201701572D0 (en) | 2017-01-31 | 2017-03-15 | Immunovia Ab | Methods, arrays and uses thereof |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0039578B1 (en) | 1980-05-02 | 1985-04-10 | Edward P. Davis | Leg aid device |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| CA1202235A (en) * | 1983-08-30 | 1986-03-25 | Paul S. Satoh | Immunoassay for complement fragments |
| US5856090A (en) | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| WO2001006262A1 (en) | 1999-02-19 | 2001-01-25 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration |
| JP4619651B2 (ja) | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| WO2004031411A2 (en) | 2002-09-30 | 2004-04-15 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human pancreatic cancers |
| US20050260639A1 (en) * | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
| ATE419533T1 (de) | 2002-10-31 | 2009-01-15 | Hoffmann La Roche | Verfahren/präparat zur erkennung von pankreaskrebs |
| WO2004055519A2 (en) * | 2002-12-17 | 2004-07-01 | Sinogenomax Co. Ltd. | Specific markers for pancreatic cancer |
| JP3857241B2 (ja) * | 2003-02-17 | 2006-12-13 | スパンション インク | 昇圧電源の振幅を小さくしたチャージポンプ回路 |
| JP4194080B2 (ja) * | 2003-02-19 | 2008-12-10 | 茂 森村 | 膵癌検出用マーカー |
| AU2004229501B2 (en) | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
| US20040248205A1 (en) * | 2003-04-16 | 2004-12-09 | Stern Lawrence J. | Major histocompatibility complex (MHC)-peptide arrays |
| WO2004099432A2 (en) | 2003-05-02 | 2004-11-18 | The Johns Hopkins University | Identification of biomarkers for detecting pancreatic cancer |
| KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
| DE602004025706D1 (enExample) * | 2003-07-10 | 2010-04-08 | Central Inst Exper Animals | |
| US20050277137A1 (en) * | 2003-08-15 | 2005-12-15 | University Of Pittsburgh | Diagnostic multimarker serological profiling |
| WO2005063812A2 (en) * | 2003-12-24 | 2005-07-14 | Applied Research Systems Ars Holding N.V. | Cc-chemokine-binding tick proteins |
| US20060106119A1 (en) * | 2004-01-12 | 2006-05-18 | Chang-Jie Guo | Novel integration for CO and H2 recovery in gas to liquid processes |
| BRPI0520902B1 (pt) | 2004-05-28 | 2021-11-30 | Agensys, Inc | Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo que se liga a proteínas psca para diagnóstico de câncer, método para produção dos mesmos, hibridoma, polinucleotídeo, vetor, composição, ensaio para detectar a presença de uma proteína psca e método de detecção de uma proteína psca |
| US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| JP2008535853A (ja) | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 癌関連遺伝子 |
| JP2008535857A (ja) * | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 癌の診断、検出および処置におけるｃａｃｎａ１ｅ |
| US8632983B2 (en) | 2005-04-15 | 2014-01-21 | Van Andel Research Institute | Biomarkers for pancreatic cancer and diagnostic methods |
| CN1851455B (zh) | 2005-04-22 | 2010-11-10 | 复旦大学附属中山医院 | 一种肿瘤标志物-血清蛋白指纹图谱的检测方法 |
| EP1877796A2 (en) * | 2005-05-05 | 2008-01-16 | Philadelphia Health & Education Corporation d/b/a | Diagnosis of liver pathology through assessment of protein glycosylation |
| EP1736780A1 (en) * | 2005-06-24 | 2006-12-27 | Eppendorf Array Technologies S.A. | Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus |
| JP2007051880A (ja) * | 2005-08-15 | 2007-03-01 | Tokyo Univ Of Science | 膵臓癌の検出方法、膵臓癌の診断キット |
| KR20090003178A (ko) | 2006-01-11 | 2009-01-09 | 게노믹 헬쓰, 인코포레이티드 | 직장결장암 예후에 대한 유전자 발현 마커 |
| WO2007107774A2 (en) | 2006-03-22 | 2007-09-27 | Cartela R & D Ab | Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer |
| ATE487139T1 (de) | 2006-04-18 | 2010-11-15 | Perseus Proteomics Inc | Diagnostikum und therapeutikum gegen bauchspeicheldrüsenkrebs |
| US20080038301A1 (en) | 2006-08-08 | 2008-02-14 | The Procter & Gamble Company | Personal care product comprising collapsible water-containing capsules |
| KR100819122B1 (ko) | 2006-09-30 | 2008-04-04 | 남명진 | 췌장암 진단용 키트 |
| RU2473555C2 (ru) * | 2006-12-19 | 2013-01-27 | ДжинГоу, Инк. | Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных |
| CN101246176B (zh) | 2007-02-13 | 2013-06-05 | 许洋 | 鳞状细胞癌抗原阴性宫颈癌血清蛋白质检测的质谱试剂及其制备方法 |
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| GB0709092D0 (en) | 2007-05-11 | 2007-06-20 | Borrebaeck Carl | Diagnosis and method of disease |
| NZ555363A (en) | 2007-05-24 | 2009-11-27 | Pacific Edge Biotechnology Ltd | Prognosis prediction for melanoma cancer |
| EP2637020A3 (en) | 2007-06-29 | 2014-01-08 | Correlogic Systems Inc. | Predictive markers for ovarian cancer |
| EP2217625B1 (en) | 2007-11-08 | 2021-08-04 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| GB0723179D0 (en) | 2007-11-27 | 2008-01-02 | Immunovia Ab | Diagnostic methods and arrays for use in the same |
| WO2009111067A2 (en) | 2008-03-07 | 2009-09-11 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation |
| GB0815846D0 (en) | 2008-09-01 | 2008-10-08 | Immunovia Ab | diagnosis, prognosis and imaging of disease |
| CN101676300B (zh) | 2008-09-16 | 2012-05-02 | 中国科学院生物物理研究所 | 一种抑制人结肠肿瘤生长的新型抗体及其在制备用于早期诊断结直肠癌、子宫内膜癌以及胰腺癌的诊断剂中的应用 |
| CN101451975B (zh) | 2008-12-29 | 2012-01-25 | 浙江大学 | 一种检测胃癌预后与分期血清蛋白质的方法 |
| US20120004289A1 (en) | 2009-03-06 | 2012-01-05 | The Johns Hopkins University | Annexin a11 and associated genes as biomarkers for cancer |
| EP3444359A1 (en) | 2009-03-12 | 2019-02-20 | Cancer Prevention And Cure, Ltd. | Methods of identification of non-small cell lung cancer |
| CN101880707A (zh) | 2009-05-05 | 2010-11-10 | 中国人民解放军第二军医大学 | microRNA-21在鉴别胰腺癌中的应用 |
| CN101613748A (zh) | 2009-06-09 | 2009-12-30 | 中国人民解放军第二军医大学 | 一种检测胰腺癌血清标志物的方法 |
| RU2421149C2 (ru) | 2009-07-16 | 2011-06-20 | Ольга Васильевна Кокуева | Способ дифференциальной диагностики рака поджелудочной железы и хронического панкреатита |
| SG168431A1 (en) | 2009-07-23 | 2011-02-28 | Univ Singapore | Cancer biomarker and the use thereof |
| EP2483690A1 (de) | 2009-09-29 | 2012-08-08 | Protagen AG | Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung |
| CN102279264A (zh) | 2010-06-09 | 2011-12-14 | 李彬 | 48种恶性肿瘤标志物抗体芯片的制备方法 |
| CN106011233A (zh) | 2010-08-13 | 2016-10-12 | 莫尔豪斯医学院 | 中风的生物标记 |
| WO2012031374A1 (zh) | 2010-09-09 | 2012-03-15 | 北京同为时代生物技术有限公司 | 用于诊断上皮源性癌症的血液标志物及其单克隆抗体 |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| CN102201038B (zh) | 2011-04-27 | 2013-06-05 | 浙江大学 | 脑瘤p53蛋白表达检测方法 |
| CN102286464B (zh) | 2011-06-30 | 2013-07-17 | 眭维国 | 尿毒症长链非编码核糖核酸差异性表达图谱模型及其构建方法 |
| WO2013052480A1 (en) | 2011-10-03 | 2013-04-11 | The Board Of Regents Of The University Of Texas System | Marker-based prognostic risk score in colon cancer |
| WO2013106844A2 (en) | 2012-01-13 | 2013-07-18 | Oncocyte Corporation | Methods and compositions for the treatment and diaginosis of pancreatic cancer |
| EP2929350A4 (en) | 2012-12-04 | 2016-11-16 | Caris Mpi Inc | MOLECULAR PROFILING OF CANCER |
| TWI658049B (zh) | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| CA2902841A1 (en) | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| WO2014151079A2 (en) | 2013-03-15 | 2014-09-25 | The United States Of America, As Represented By The Sec. Dept. Of Health And Human Services | Ratio based biomarkers and methods of use thereof |
| JP6683986B2 (ja) | 2013-07-10 | 2020-04-22 | 国立大学法人 東京大学 | がん幹細胞分子マーカー |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| WO2015112429A1 (en) | 2014-01-23 | 2015-07-30 | Newomics Inc | Methods and systems for diagnosing diseases |
| WO2015157557A1 (en) | 2014-04-09 | 2015-10-15 | Myriad Rbm, Inc. | Methods of diagnosing pancreatic cancer and methods related thereto |
| WO2015171736A2 (en) | 2014-05-07 | 2015-11-12 | University Of Utah Research Foundation | Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma |
| KR20150129932A (ko) | 2014-05-12 | 2015-11-23 | 연세대학교 산학협력단 | 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 |
| GB201501930D0 (en) | 2015-02-05 | 2015-03-25 | Univ London Queen Mary | Biomarkers for pancreatic cancer |
| CN105092845A (zh) | 2015-07-10 | 2015-11-25 | 深圳市贝沃德克生物技术研究院有限公司 | 胰腺癌蛋白生物标记物、用途及其检测芯片和检测装置 |
| CN105092844A (zh) | 2015-07-10 | 2015-11-25 | 深圳市贝沃德克生物技术研究院有限公司 | 胰腺癌蛋白生物标记物的检测试剂盒及检测系统 |
| GB201516801D0 (en) | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
| GB201608192D0 (en) * | 2016-05-10 | 2016-06-22 | Immunovia Ab | Method, array and use thereof |
| GB201701572D0 (en) | 2017-01-31 | 2017-03-15 | Immunovia Ab | Methods, arrays and uses thereof |
| US12416636B2 (en) | 2018-05-31 | 2025-09-16 | University Of Florida Research Foundation, Inc. | Personalized treatment of pancreatic cancer |
| CN111171053B (zh) | 2020-01-06 | 2021-03-05 | 丽水市中心医院 | 一种化合物在制备治疗胰腺癌药物中的应用 |
| GB202010970D0 (en) * | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
-
2008
- 2008-03-25 WO PCT/GB2008/001090 patent/WO2008117067A2/en not_active Ceased
- 2008-03-25 AU AU2008231575A patent/AU2008231575A1/en not_active Abandoned
- 2008-03-25 EP EP08718919.7A patent/EP2140269B1/en active Active
- 2008-03-25 DK DK08718919.7T patent/DK2140269T3/da active
- 2008-03-25 CN CN201710115906.1A patent/CN107102142A/zh active Pending
- 2008-03-25 ES ES08718919.7T patent/ES2442919T3/es active Active
- 2008-03-25 JP JP2010500358A patent/JP6115801B2/ja not_active Expired - Fee Related
- 2008-03-25 US US12/593,448 patent/US20100105571A1/en not_active Abandoned
- 2008-03-25 CN CN200880013776A patent/CN101680896A/zh active Pending
- 2008-03-25 CA CA2681899A patent/CA2681899C/en active Active
- 2008-03-25 PL PL08718919T patent/PL2140269T3/pl unknown
- 2008-03-25 EP EP20214718.7A patent/EP3851856A3/en not_active Withdrawn
- 2008-03-25 EP EP12163644A patent/EP2490025A3/en not_active Withdrawn
-
2014
- 2014-07-18 AU AU2014204510A patent/AU2014204510C1/en not_active Ceased
-
2015
- 2015-05-28 JP JP2015108468A patent/JP2015187611A/ja active Pending
-
2016
- 2016-10-07 AU AU2016238939A patent/AU2016238939B2/en not_active Ceased
-
2017
- 2017-01-06 JP JP2017000956A patent/JP6465902B2/ja not_active Expired - Fee Related
- 2017-05-08 US US15/589,084 patent/US20170307620A1/en not_active Abandoned
-
2019
- 2019-09-23 US US16/578,768 patent/US11525832B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3851856A3 (en) | 2021-11-03 |
| JP2017067792A (ja) | 2017-04-06 |
| EP2140269A2 (en) | 2010-01-06 |
| CN101680896A (zh) | 2010-03-24 |
| JP2010522875A (ja) | 2010-07-08 |
| JP6115801B2 (ja) | 2017-04-19 |
| WO2008117067A3 (en) | 2008-11-20 |
| CA2681899C (en) | 2018-06-19 |
| AU2014204510A1 (en) | 2014-08-07 |
| EP2140269B1 (en) | 2013-11-20 |
| ES2442919T3 (es) | 2014-02-14 |
| WO2008117067A2 (en) | 2008-10-02 |
| EP3851856A2 (en) | 2021-07-21 |
| CA2681899A1 (en) | 2008-10-02 |
| AU2008231575A1 (en) | 2008-10-02 |
| AU2014204510B2 (en) | 2016-10-27 |
| WO2008117067A9 (en) | 2008-12-31 |
| AU2016238939A1 (en) | 2016-11-03 |
| US20200018760A1 (en) | 2020-01-16 |
| AU2014204510C1 (en) | 2017-01-19 |
| PL2140269T3 (pl) | 2014-07-31 |
| JP6465902B2 (ja) | 2019-02-06 |
| AU2016238939B2 (en) | 2018-08-02 |
| DK2140269T3 (da) | 2013-12-16 |
| WO2008117067A8 (en) | 2009-04-16 |
| EP2490025A2 (en) | 2012-08-22 |
| EP2490025A3 (en) | 2012-11-28 |
| US20170307620A1 (en) | 2017-10-26 |
| US20100105571A1 (en) | 2010-04-29 |
| JP2015187611A (ja) | 2015-10-29 |
| US11525832B2 (en) | 2022-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107102142A (zh) | 检测腺癌的蛋白标志/标记 | |
| KR102014890B1 (ko) | 췌장암의 존재를 결정하기 위한 방법, 어레이 및 그의 용도 | |
| CN105917230B (zh) | 用于确定胰腺癌的方法、阵列和其用途 | |
| CN101438167A (zh) | 利用reg4蛋白诊断胰腺癌症的方法 | |
| US20100304979A1 (en) | Diagnostic Methods and Arrays for Use in the Same | |
| KR20090034961A (ko) | 폐암 진단 검사 | |
| CN103245784A (zh) | 肺癌的诊断分析法 | |
| CN103038642A (zh) | 方法、阵列及其用途 | |
| CN106680515B (zh) | 用于肺癌诊断的多分子标志物组合 | |
| CN110241217A (zh) | 早期诊断胰腺癌的分子标记 | |
| CN101374962A (zh) | 肺癌的诊断分析法 | |
| HK1142674A (en) | Protein signature/markers for the detection of adenocarcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170829 |